A dual-level Bayesian network meta-analysis of first-line immunotherapy in advanced hepatocellular carcinoma: strategy-level and regimen-level evidence.

AiTan (rivoceranib) - Elevar Therapeutics

Tecentriq (atezolizumab) - Roche

sorafenib - Generic mfg.

Byvasda (bevacizumab biosimilar) - Innovent Biologics, Etana

AiRuiKa (camrelizumab) - Elevar Therapeutics

Tyvyt (sintilimab) - Innovent Biologics, Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/42620506

Qiangqiang Zhang; Rui Wang; Yanyan Hu; Yuli Ge

Aug 21, 2026